“These patents represent valuable intellectual property for Single Cell,” commented Jim Bowlby, COO of Single Cell Technology. “For the first time, our new method of identifying and optimizing antibodies has been carefully reviewed and validated. These United States patents will greatly accelerate our international filings.”
Single Cell has additional pending patent applications that extend its core antibody screening technology to the rapid and parallel functional assessment of therapeutic potentials by miniaturized cell-based assays. “The novelty of our process, as recognized by the U.S. Patent and Trademark Office, brings us one step closer to preventing infectious diseases, curing chronic illnesses, and improving everyone’s quality of life,” said Dr. Chun-Nan Chen, CEO of Single Cell Technology. ”The antibody therapeutic market, growing at 20% per year, needs ways to sample novel antibody repertoires. Single Cell is pleased to provide one of the most innovative methods that is host agnostic.”
About Single Cell Technology, Inc.
Single Cell has pioneered a new approach to antibody discovery. Its technology is able to analyze the antibodies and mRNA from individual antibody secreting cells. Antibodies are rapidly screened against multiple molecules to measure their affinity and specificity, and mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS) technology and correctly paired. In addition to human and mouse cells, Single Cell’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. Founders Chun-Nan Chen and Jim Bowlby integrated advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. Single Cell’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the market for innovative antibody discovery. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Chun-Nan Chen, chunnan.chen@
Jim Bowlby, firstname.lastname@example.org